Consultative service, online or in-person, provides life sciences organizations with TMF roadmap
PLEASANTON, CA – Jan. 21, 2016– Veeva Systems introduces the Veeva TMF Maturity Model – a complimentary consultative service designed to assess the state of a life sciences organization’s trial master file (TMF) strategy and provide a roadmap for improvement. The Veeva TMF Maturity Model gives practical, step-by-step guidance to help companies transform their TMF from a static archive into a strategic asset that can help increase the efficiency of clinical trials. It is available as a self-service online tool or as a more detailed, in-person evaluation with a seasoned subject matter expert.
The Veeva TMF Maturity Model assessment provides companies with a tailored report, outlining the current state of their TMF, comparison to industry benchmarks, and a roadmap for improvement. More than 60 life sciences companies have already completed the evaluation.
Data amassed to date shows companies who have completed the Veeva TMF Maturity Model evaluation are only halfway along the full TMF maturity curve, averaging 2.54 on a scale of one to five. These empirical findings are consistent with industry-wide survey data from the annual Veeva 2015Paperless TMF Survey showing an industry shift away from maintaining paper documentation, however, with still too much reliance on manual processes. More than half of survey respondents (59%) report archiving documents electronically, yet far fewer have fully digitized other key activities such as e-signatures (21%), document creation (25%), and collaboration (30%).
“In just one year, the industry has seen a dramatic uptick in electronic TMF application adoption,” said Jason Methia, director of Vault eTMF strategy at Veeva. “The Veeva TMF Maturity Model provides the industry with a reliable framework to make systematic strides towards shedding paper and transitioning toward automated methods and systems.” Kathryn King, vice president of Vault Clinical at Veeva, will discuss how to move along the TMF continuum during ExL Pharma’s 5th Trial Master File Summit, at 10:45 AM on January 21, 2016 at the Westin Arlington Gateway in Virginia.
Life sciences organizations can visit VeevaTMFmaturity.com to access the self-service Veeva TMF Maturity Model or email TMFMaturity@veeva.com to request a one-on-one assessment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.